Lilly’s Rheumatoid Arthritis Drug Shortens Covid-19 Hospitalization When Combined With Antiviral Med

The pharmaceutical company said its drug baricitinib, combined with remdesivir, reduces median hospital stays by one day compared to remdesivir alone, and is pursuing an emergency use authorization with the FDA.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive